3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Genitourinary
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
58
Nivolumab
37
aldesleukin
16
Cyclophosphamide
15
atezolizumab
12
Specimen Handling
11
Radiosurgery
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
Ipilimumab
9
Interleukin-2
9
fludarabine
8
fludarabine phosphate
7
Docetaxel
7
Carboplatin
7
avelumab
6
Radiotherapy
6
durvalumab
5
Peripheral Blood Stem Cell Transplantation
5
Immune Checkpoint Inhibitors
5
Cisplatin
5
Bevacizumab
5
tislelizumab
4
temsirolimus
4
spartalizumab
4
Sirolimus
4
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Cryosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
alectinib
×
Dermatologic
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts